Question 192 of 433
Is hormone therapy safe?
The short answer
For many healthy women with bothersome symptoms who start before age 60 or within ten years of menopause, the benefit–risk balance is favorable. That is a starting point for a personal decision, not a declaration that hormones are risk-free.
The Women’s Health Initiative changed practice because it identified real benefits and harms in randomized trials. Its average participant was older than the typical woman seeking first treatment for hot flashes, and the studied oral formulations do not represent every modern option. Subsequent analyses clarified the importance of age, timing, formulation, and whether a progestogen is used. They did not turn every unfavorable finding into a mistake.
Hormone therapy is the most effective treatment for hot flashes and night sweats and can prevent bone loss and fractures. Breast-cancer history, unexplained bleeding, thromboembolic disease, stroke, coronary disease, liver disease, and other factors can alter suitability. A clinician should review the relevant history before prescribing.
The FDA requested broad labeling revisions in November 2025 and approved revised labeling for an initial group of products in February 2026. Removal of language from a boxed warning does not mean that every relevant risk disappeared; product-specific warnings and contraindications still matter.
The practical question is which treatment offers this woman meaningful relief at an acceptable risk. Hormone therapy should not be started solely as a strategy to prevent heart disease, dementia, or death.
“This book is for education. It is not medical advice, and reading it does not make you my patient or create a doctor-patient relationship.” From the book’s medical disclaimer. Full disclaimer
ROBUST HUMAN TRIALS / GUIDELINE — Eligible symptomatic women: hormone therapy benefits and risks depend on timing, formulation, and history.Evidence grade (draft mapping)ARobust human trialsPart 14, Q192 · Sources: R5, R6
Sources cited
- R5 Manson JE et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials. JAMA. 2017;318:927–938. doi:10.1001/jama.2017.11217. PubMed 28898378DOI 10.1001/jama.2017.11217✓ Verified
- R6 US Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. February 12, 2026. Link pending verification
From Longevity Unmasked by Afshine Ash Emrani, MD, FACC. Medical disclaimer. This book is for education. It is not medical advice, and reading it does not make you my patient or create a doctor-patient relationship. Nothing here is meant to diagnose, treat, cure, or prevent any disease. Medicine is personal: a test, drug, supplement, or exercise plan that helps one person can harm another. Do not start, stop, or change any medication or treatment because of something you read in these pages. Talk with a licensed clinician who knows your history first. If you think you are having a medical emergency, call 911. The author disclaims responsibility for any loss or harm arising from use of the information in this book.